CLASSYS Inc. (KOSDAQ:214150)
53,700
-1,000 (-1.83%)
Sep 18, 2025, 3:30 PM KST
CLASSYS Revenue
CLASSYS had revenue of 83.28B KRW in the quarter ending June 30, 2025, with 41.78% growth. This brings the company's revenue in the last twelve months to 294.21B, up 43.96% year-over-year. In the year 2024, CLASSYS had annual revenue of 242.94B with 34.87% growth.
Revenue (ttm)
294.21B
Revenue Growth
+43.96%
P/S Ratio
11.95
Revenue / Employee
746.74M
Employees
394
Market Cap
3,516.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 242.94B | 62.82B | 34.87% |
Dec 31, 2023 | 180.12B | 38.32B | 27.02% |
Dec 31, 2022 | 141.80B | 41.21B | 40.96% |
Dec 31, 2021 | 100.60B | 24.14B | 31.57% |
Dec 31, 2020 | 76.46B | -4.67B | -5.76% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |